These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29943733)

  • 1. The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the
    Afolabi PR; Scorletti E; Smith DE; Almehmadi AA; Calder PC; Byrne CD
    J Breath Res; 2018 Jul; 12(4):046002. PubMed ID: 29943733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of the repeatability of the
    Afolabi PR; Scorletti E; Calder PC; Byrne CD
    Isotopes Environ Health Stud; 2019 May; 55(2):150-160. PubMed ID: 30880467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis.
    Banasch M; Ellrichmann M; Tannapfel A; Schmidt WE; Goetze O
    Eur J Med Res; 2011 Jun; 16(6):258-64. PubMed ID: 21810560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors independently associated with cardiorespiratory fitness in patients with non-alcoholic fatty liver disease.
    Afolabi PR; Scorletti E; Calder PC; Byrne CD
    Liver Int; 2020 Dec; 40(12):2998-3007. PubMed ID: 32706931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis.
    Portincasa P; Grattagliano I; Lauterburg BH; Palmieri VO; Palasciano G; Stellaard F
    Clin Sci (Lond); 2006 Aug; 111(2):135-43. PubMed ID: 16603025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial function reflected by the decarboxylation of [13C]ketoisocaproate is impaired in alcoholics.
    Witschi A; Mossi S; Meyer B; Junker E; Lauterburg BH
    Alcohol Clin Exp Res; 1994 Aug; 18(4):951-5. PubMed ID: 7978109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (
    Molina-Molina E; Shanmugam H; Di Ciaula A; Grattagliano I; Di Palo DM; Palmieri VO; Portincasa P
    JHEP Rep; 2021 Feb; 3(1):100203. PubMed ID: 33490935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.
    Di Ciaula A; Calamita G; Shanmugam H; Khalil M; Bonfrate L; Wang DQ; Baffy G; Portincasa P
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: A palmitate breath test study.
    Naguib G; Morris N; Yang S; Fryzek N; Haynes-Williams V; Huang WA; Norman-Wheeler J; Rotman Y
    Liver Int; 2020 Mar; 40(3):590-597. PubMed ID: 31762148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic Fatty liver disease.
    Tribonias G; Margariti E; Tiniakos D; Pectasides D; Papatheodoridis GV
    J Clin Gastroenterol; 2014 Jan; 48(1):59-65. PubMed ID: 24335903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver function as assessed by breath tests in patients with hepatocellular carcinoma.
    Palmieri VO; Grattagliano I; Minerva F; Pollice S; Palasciano G; Portincasa P
    J Surg Res; 2009 Dec; 157(2):199-207. PubMed ID: 19540521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease.
    Kempiński R; Neubauer K; Wieczorek S; Dudkowiak R; Jasińska M; Poniewierka E
    Adv Clin Exp Med; 2016; 25(1):77-81. PubMed ID: 26935501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender affects 13C-ketoisocaproic acid breath test.
    Candelli M; Armuzzi A; Miele L; Nista EC; Pignataro G; Zileri Dal Verme L; Grieco A; Gasbarrini G; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2007; 11(6):401-6. PubMed ID: 18306908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors.
    Prasetya IB; Hasan I; Wisnu W; Rumende CM
    Acta Med Indones; 2017 Apr; 49(2):91-98. PubMed ID: 28790222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.
    Park GJ; Wiseman E; George J; Katelaris PH; Seow F; Fung C; Ngu MC
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1411-6. PubMed ID: 21557768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease.
    Kim G; Kim KJ; Rhee Y; Lim SK
    PLoS One; 2017; 12(7):e0182202. PubMed ID: 28759632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population.
    Atsawarungruangkit A; Chenbhanich J; Dickstein G
    World J Gastroenterol; 2018 Aug; 24(32):3663-3670. PubMed ID: 30166861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.